Ezrin, which antagonizes Willin/FRMD6′s activation of MST1/2 in HEK-293 cells [35], is upregulated during disease progression in a tauopathy (P301L) mouse model and in AD patients [78]. Here, FRMD6 is linked to Alzheimer disease.